

CYP.04335 Synthetic and Commercial Control Range Establishment or Verification**Phase II**

If synthetic or commercial controls are used for quantitative testing, the laboratory establishes or verifies an acceptable control range for each lot of synthetic or commercial control material.

NOTE: The laboratory must verify control ranges supplied by the manufacturer if provided and establish an acceptable range by repetitive analysis if control ranges are not provided by the manufacturer.

Control values supplied by the manufacturer may be used without verification for qualitative (eg, positive or negative) testing.

Evidence of Compliance:

- ✓ Records for control range establishment or verification of each lot, as applicable

REFERENCES

- 1) Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Precision of Quantitative Measurement Procedures. Approved Guideline*. 3rd ed. CLSI document EP05-A3. Clinical and Laboratory Standards Institute, Wayne, PA; 2014.
- 2) Clinical and Laboratory Standards Institute (CLSI). *Statistical Quality Control for Quantitative Measurement Procedures, Principles and Definitions*. 4th ed. CLSI guideline C24. Clinical and Laboratory Standards Institute, Wayne, PA; 2016.

CYP.04340 QC - Antibodies**Phase II**

Appropriate negative controls are used.

NOTE: Negative controls must assess the presence of nonspecific staining in patient specimens as well as the specificity of each antibody with the exception listed below. Results of controls must be recorded, either in internal laboratory records, or in the patient report. A statement in the report such as, "All controls show appropriate reactivity" is sufficient.

For laboratories using older biotin-based detection systems, it is important to use a negative reagent control to assess nonspecific or aberrant staining in patient specimens related to the antigen retrieval conditions and/or detection system used. A separate section of patient specimen is processed using the same reagent and epitope retrieval protocol as the patient test slide, except that the primary antibody is omitted, and replaced by any one of the following:

- *An unrelated antibody of the same isotype as the primary antibody (for monoclonal primary antibodies)*
- *An unrelated antibody from the same animal species as the primary antibody (for polyclonal primary antibodies)*
- *The negative control reagent included in the staining kit*
- *The diluent/buffer solution in which the primary antibody is diluted*

In general, a separate negative reagent control should be run for each specimen being immunostained; however, for cases in which there is simultaneous staining of multiple specimens from the same specimen with the same antibody, performing a single negative control on one of the specimens may be sufficient provided that all such specimens are fixed and processed identically. This exception does not apply to stains on different types of tissues or those using different antigen retrieval protocols or antibody detection systems. The laboratory director must determine which cases will have only one negative reagent control, and this must be specified in the department's procedure manual.

The negative reagent control would ideally control for each reagent protocol and antibody retrieval condition; however, large antibody panels often employ multiple antigen retrieval procedures. In such cases, a reasonable minimum control would be to perform the negative reagent control using the most aggressive retrieval procedure in the particular antibody panel. Aggressiveness of antigen retrieval (in decreasing order) is as follows: pressure cooker; enzyme digestion; boiling; microwave; steamer; water bath. High pH retrieval should be considered more aggressive than comparable retrieval in citrate buffer at pH 6.0.

Immunochemical tests using polymer-based detection systems (biotin-free) are sufficiently free of background reactivity to obviate the need for a negative reagent control and such controls may be omitted at the discretion of the laboratory director following appropriate validation.

It is also important to assess the specificity of each antibody by a negative cellular/tissue control, which must show no staining of cells/tissues known to lack the antigen. The negative control is processed using the same fixation, epitope retrieval and immunostaining protocols as the patient tissue. Unexpected positive staining of such tissues indicates that the test has lost specificity, perhaps because of improper antibody concentration or excessive antigen retrieval. Intrinsic properties of the test tissue may also be the cause of "non-specific" staining. For example, cells/tissues with high endogenous biotin activity such as liver or renal tubules may simulate positive staining when using a detection method based on biotin labeling.

A negative cellular sample or tissue control must be processed for each antibody in a given run. Any of the following can serve as a negative cellular/tissue control:

- 1. Multitissue blocks. These can provide simultaneous positive and negative tissue controls, and are considered "good practice" (see below).*
- 2. The positive control slide or patient test slides, if these slides contain cellular or tissue elements that should not react with the antibody.*
- 3. A separate negative cytologic preparation or tissue control slide.*

The type of negative cellular/tissue control used (ie, separate sections, internal controls or multitissue blocks) must be specified in the laboratory manual.

Multitissue blocks or tissue microarrays (TMAs) can have a major role in maintaining quality. When used as a combined positive and negative tissue control as mentioned above, they can serve as a permanent record of the sensitivity and specificity of every stain, particularly when mounted on the same slide as the patient tissue. When the components are chosen appropriately, multitissue blocks may be used for many different primary antibodies, decreasing the number of different control blocks needed by the laboratory. Multitissue blocks are also ideal for determining optimal titers of primary antibodies since they allow simultaneous evaluation of many different pieces of tissue. Finally, they are a useful and efficient means to screen new antibodies for sensitivity and specificity or new lots of antibody for consistency, which should be done before putting any antibody into diagnostic use.

Evidence of Compliance:

- ✓ Patient reports or worksheet with control results **AND**
- ✓ Immunochemical-stained slides with appropriate negative controls

REFERENCES

- 1) Leong AS-Y, Cooper K, Leong FJW-M. Manual of Diagnostic Antibodies for Immunohistology. 2nd ed. London: Greenwich Medical Media; 2003
- 2) Dabbs DJ, ed. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. Philadelphia: Saunders/Elsevier; 2010
- 3) Burry RW. Specificity controls for immunocytochemical methods. *J Histochem Cytochem* 2000;48:163-166
- 4) Weirauch M. Multitissue control block for immunohistochemistry. *Lab Med*. 1999;30:448-449
- 5) Miller RT. Multitumor "sandwich" blocks in immunohistochemistry. Simplified method and preparation and practical uses. *Appl Immunohistochem* 1993;1: 156-159
- 6) Chan JKC, Wong CSC, Ku WT, Kwan MY. Reflections on the use of controls in immunohistochemistry and proposal for application of a multitissue spring-roll control block. *Ann Diagn Pathol* 2000;4: 329-336
- 7) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 2023(Dec 28): [42CFR493.1273(a)].
- 8) Torlakovic EE, Francis G, Garratt J, et al. International Ad Hoc Expert Panel. Standardization of negative controls in diagnostic immunohistochemistry recommendations from the international ad hoc expert panel. *Appl Immunohistochem Mol Morphol*. 2014;22(4):241-52.
- 9) Allen M, Gown, MD. Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent it. *Arch Pathol Lab Med*. 2016;140(9):893-898.

CYP.04350 Endogenous Biotin

Phase I



If the laboratory uses an avidin-biotin complex (ABC) detection system (or a related system such as streptavidin-biotin or neutravidin-biotin), nonspecific false-positive staining from endogenous biotin is addressed.